ClinicalTrials.gg
CompletedNCT04198558Updated Oct 16, 2023

A Study of the Safety, Tolerability and Pharmacokinetics of MEDI0618 in Healthy Volunteers

A Phase 1 interventional study of MEDI0618 and Placebo in Chronic Pain, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-16.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies in Chronic Pain with a site in Germany — 11 open to participants now, 14 under way, 8 of them phase 3. Chronic Pain · Germany.

Enrollment
33rd of 50
64 · median 91
Started
2019
with 4 others
Phase 1
4 of 70
none open now
Registered
47th of 70
by date
Lead sponsor
3 of 70
AstraZeneca

Among the 70 studies in Chronic Pain with a site in Germany, this one is the 33rd largest by enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2019, is one of 4 in phase 1, and was the 47th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

11 of the 70 studies in Chronic Pain with a site in Germany are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Chronic Pain with a site in Germany, or all of them as a file.
02

Study summary

This is a randomised, placebo-controlled study of the safety and tolerability of single doses of MEDI0618 in healthy volunteer subjects.

Read the detailed description

This is a randomised, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of single ascending doses of MEDI0618 in healthy male and female volunteers.

This study will include 9 planned cohorts; 8 cohorts will receive single ascending doses of MEDI0618 or placebo by intravenous administration, 1 cohort will receive MEDI0618 or placebo by subcutaneous administration.All subjects will undergo scheduled safety, tolerability, pharmacokinetic and immunogenicity assessments while in the clinical unit and as outpatients to the end of the follow-up period.

03

Conditions studied

  • Chronic Pain

Browse trials for

Keywords

  • Double-blind
  • Placebo-controlled
  • Safety and Tolerability Study
  • Healthy Volunteers
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy men and women of non- aged 18 to 55 years
  • Normal 12-lead at screening and on day of dosing
  • Physical examinations with no significant findings at screening
  • Be able to understand and comply with protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study with an product (IP) within half-lives of the IP or 3 months, whichever is longer, prior to screening
  • Requires treatment with another biological therapeutic agent
  • Inability to comply with study-related requirements
  • History of severe allergy or reactions
  • History of significant psychiatric disorder
  • Presence of any illness
  • History of cancer
  • Any clinically important abnormality physical examination, vital signs, or laboratory test
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Dose Level 1

    MEDI0618 or placebo

    Drug: MEDI0618 · Drug: Placebo

  • Experimental
    Dose Level 2

    MEDI0618 or placebo

    Drug: MEDI0618 · Drug: Placebo

  • Experimental
    Dose Level 3

    MEDI0618 or placebo

    Drug: MEDI0618 · Drug: Placebo

  • Experimental
    Dose Level 4

    MEDI0618 or placebo

    Drug: MEDI0618 · Drug: Placebo

  • Experimental
    Dose Level 5

    MEDI0618 or placebo

    Drug: MEDI0618 · Drug: Placebo

  • Experimental
    Dose Level 6

    MEDI0618 or placebo

    Drug: MEDI0618 · Drug: Placebo

  • Experimental
    Dose Level 7

    MEDI0618 or placebo

    Drug: MEDI0618 · Drug: Placebo

  • Experimental
    Dose Level 8

    MEDI0618 or placebo

    Drug: MEDI0618 · Drug: Placebo

  • Experimental
    Dose Level 9

    MEDI0618 or placebo

    Drug: MEDI0618 · Drug: Placebo

Interventions

  • MEDI0618 A novel human immunoglobulin antibody

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Adverse Events

    Time frame: Up to 85 days

  2. Incidence of Treatment-Emergent Serious Adverse Events

    Serious Adverse Events

    Time frame: Up to 85 days

  3. Vital Signs

    Heart Rate in beats per minute

    Time frame: Up to 85 days

  4. Vital Signs

    Blood pressure in mm Hg

    Time frame: Up to 85 days

  5. Body Weight

    Weight in kg

    Time frame: Up to 85 days

  6. Height

    Height in meters Height and weight will be combined to report BMI in kg/m\^2

    Time frame: Up to 85 days

  7. Clinical Chemistry

    Measurement of Albumin, Protein, Aspartate transaminase, Alanine transaminase, Alkaline phosphatase, Bilirubin, Calcium, Creatine phosphokinase, C-reactive protein, Glucose, Blood urea nitrogen, Phosphate, Potassium, Sodium, Chloride and Bicarbonate

    Time frame: Up to 85 days

  8. Haematology

    Measurement of Haemoglobin, Haematocrit, Leukocyte count, Platelet count, Erythrocyte count, Reticulocyte count, Mean corpuscular haemoglobin

    Time frame: Up to 85 days

  9. Thyroid Function

    Measurement of Thyroid-stimulating hormone and free thyroxine

    Time frame: Up to 85 days

  10. Renal Function

    Measurement of Glomerular filtration rate

    Time frame: Up to 85 days

  11. Urinalysis

    Measurement of Haemoglobin, Leukocytes, Glucose, Protein and Creatinine

    Time frame: Up to 85 days

  12. 12-Lead Electrocardiogram

    Measurement of Heart rate; PR, QRS, RR, QT and QTc intervals from digital recordings

    Time frame: Up to 85 days

  13. Physical Examination

    General physical examination

    Time frame: Up to 85 days

Secondary outcomes

  1. Peak plasma concentration (Cmax)

    Peak concentration of MEDI0618 in plasma

    Time frame: Up to 85 days

  2. Time to maximum concentration (tmax)

    Time to maximum concentration of MEDI0618 in plasma

    Time frame: Up to 85 days

  3. Area under the concentration versus time curve (AUC)

    Calculated area under the concentration versus time curve for MEDI0618

    Time frame: Up to 85 days

  4. Terminal half-life

    Time required for the plasma concentration of MEDI0618 to decrease by 50%

    Time frame: Up to 85 days

  5. Bioavailability

    The fraction of MEDI0618 administered that is available to the systemic circulation

    Time frame: Up to 85 days

Other outcomes

  1. Anti-drug antibody incidence and titres

    Anti-drug (MEDI0618) antibody incidence and titres

    Time frame: Up to 85 days

07

Study locations

1 site
  • Research Site
    Berlin, 10117, Germany
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Anonymised individual patient-level data will be shared.

Time frame: After CSR sign-off.

Access criteria: Qualified researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Feb 2022, 26 months.

Of 27 industry-sponsored phase 1 interventional studies under Chronic Pain, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 26 months is above that.

Counting every sponsor, half of 60 studies reached it within 12 months; a quarter within 6 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2019
First posted
Dec 13, 2019
StartActual
Nov 29, 2019
Primary completionActual
Feb 23, 2022
CompletionActual
Feb 23, 2022
Last update
Oct 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04198558
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 13, 2019
Start date
Nov 29, 2019
Primary completion
Feb 23, 2022
Completion
Feb 23, 2022
Last update
Oct 16, 2023

Study contacts

Tharani Chessell, PhD
study director · AstraZeneca
Stanislav Ignatenko, Medical Doctor
principal investigator · Charite Research Organisation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MEDI0618

Start the discussion